Company intelligence / Profile preview

Affilogic

Ownership: Private
Development stage: Preclinical

Overview

Recent publication in Nature Scientific Report by partner Bracco Imaging on HER-2 targeting Nanofitins as diagnostic tools; New publication in Biomolecules on multispecific checkpoint inhibitor Nanofitin with tumor accumulation properties and anti-tumor activity in mice[1]

Therapeutic areas: OncologyGastroenterologyNeurologyInfectious Diseases
Modalities: Nanofitins® (antibody-mimetic binding proteins)
Industry: Biotech

Drug pipeline

3 assets

NF-800

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Bracco Imagingworldwide pharmaceutical industry leaders[1][2]

Beyond the preview

Go deeper on Affilogic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Affilogic.

Explore the full profile